28 results on '"de Gruijl, Tanja D."'
Search Results
2. Priming the tumor immune microenvironment with chemo(radio)therapy: A systematic review across tumor types
- Author
-
van den Ende, Tom, van den Boorn, Héctor G., Hoonhout, Nadine M., van Etten-Jamaludin, Faridi S., Meijer, Sybren L., Derks, Sarah, de Gruijl, Tanja D., Bijlsma, Maarten F., van Oijen, Martijn G.H., and van Laarhoven, Hanneke W.M.
- Published
- 2020
- Full Text
- View/download PDF
3. Vaccination approach to anti-angiogenic treatment of cancer
- Author
-
Wentink, Madelon Q., Huijbers, Elisabeth J.M., de Gruijl, Tanja D., Verheul, Henk M.W., Olsson, Anna-Karin, and Griffioen, Arjan W.
- Published
- 2015
- Full Text
- View/download PDF
4. Mechanisms of intimate and long-distance cross-talk between glioma and myeloid cells: How to break a vicious cycle
- Author
-
Wurdinger, Thomas, Deumelandt, Katrin, van der Vliet, Hans J., Wesseling, Pieter, and de Gruijl, Tanja D.
- Published
- 2014
- Full Text
- View/download PDF
5. Applying ceramic nanoporous microneedle arrays as a transport interface in egg plants and an ex-vivo human skin model
- Author
-
Verhoeven, Michel, Bystrova, Svetlana, Winnubst, Louis, Qureshi, Hammad, de Gruijl, Tanja D., Scheper, Rik J., and Luttge, Regina
- Published
- 2012
- Full Text
- View/download PDF
6. Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells
- Author
-
Unger, Wendy W.J., van Beelen, Astrid J., Bruijns, Sven C., Joshi, Medha, Fehres, Cynthia M., van Bloois, Louis, Verstege, Marleen I., Ambrosini, Martino, Kalay, Hakan, Nazmi, Kamran, Bolscher, Jan G., Hooijberg, Erik, de Gruijl, Tanja D., Storm, Gert, and van Kooyk, Yvette
- Published
- 2012
- Full Text
- View/download PDF
7. Tissue Resistance Decrease during Irreversible Electroporation of Pancreatic Cancer as a Biomarker for the Adaptive Immune Response and Survival.
- Author
-
Timmer, Florentine E.F., Geboers, Bart, Scheffer, Hester J., Bakker, Joyce, Ruarus, Alette H., Dijkstra, Madelon, van der Lei, Susan, Boon, Rianne, Nieuwenhuizen, Sanne, van den Bemd, Bente A.T., Schouten, Evelien A.C., van den Tol, Petrousjka M., Puijk, Robbert S., de Vries, Jan J.J., de Gruijl, Tanja D., and Meijerink, Martijn R.
- Abstract
To correlate irreversible electroporation (IRE) procedural resistance changes with survival outcomes and the IRE-induced systemic immune response in patients with locally advanced pancreatic cancer (LAPC). Data on IRE procedural tissue resistance (R) features and survival outcomes were collected from patients with LAPC treated within the context of 2 prospective clinical trials in a single tertiary center. Preprocedural and postprocedural peripheral blood samples were prospectively collected for immune monitoring. The change (ie, decrease) in R during the first 10 test pulses (ΔR 10p) and during the total procedure (ΔR total) were calculated. Patients were divided in 2 groups on the basis of the median change in R (large ΔR vs small ΔR) and compared for differences in overall survival (OS) and progression-free survival and immune cell subsets. A total of 54 patients were included; of these, 20 underwent immune monitoring. Linear regression modeling showed that the first 10 test pulses reflected the change in tissue resistance during the total procedure appropriately (P <.001; R
2 = 0.91). A large change in tissue resistance significantly correlated with a better OS (P =.026) and longer time to disease progression (P =.045). Furthermore, a large change in tissue resistance was associated with CD8+ T cell activation through significant upregulation of Ki-67+ (P =.02) and PD-1+ (P =.047). Additionally, this subgroup demonstrated significantly increased expression of CD80 on conventional dendritic cells (cDC1; P =.027) and PD-L1 on immunosuppressive myeloid-derived suppressor cells (P =.039). IRE procedural resistance changes may serve as a biomarker for survival and IRE-induced systemic CD8+ T cell and cDC1 activation. [Display omitted] [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
8. Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix.
- Author
-
Heeren, A Marijne, Punt, Simone, Bleeker, Maaike CG, Gaarenstroom, Katja N, van der Velden, Jacobus, Kenter, Gemma G, de Gruijl, Tanja D, and Jordanova, Ekaterina S
- Published
- 2016
- Full Text
- View/download PDF
9. Tumor-educated Tregs drive organ-specific metastasis in breast cancer by impairing NK cells in the lymph node niche.
- Author
-
Kos, Kevin, Aslam, Muhammad A., van de Ven, Rieneke, Wellenstein, Max D., Pieters, Wietske, van Weverwijk, Antoinette, Duits, Danique E.M., van Pul, Kim, Hau, Cheei-Sing, Vrijland, Kim, Kaldenbach, Daphne, Raeven, Elisabeth A.M., Quezada, Sergio A., Beyaert, Rudi, Jacobs, Heinz, de Gruijl, Tanja D., and de Visser, Karin E.
- Abstract
Breast cancer is accompanied by systemic immunosuppression, which facilitates metastasis formation, but how this shapes organotropism of metastasis is poorly understood. Here, we investigate the impact of mammary tumorigenesis on regulatory T cells (T regs) in distant organs and how this affects multi-organ metastatic disease. Using a preclinical mouse mammary tumor model that recapitulates human metastatic breast cancer, we observe systemic accumulation of activated, highly immunosuppressive T regs during primary tumor growth. Tumor-educated T regs show tissue-specific transcriptional rewiring in response to mammary tumorigenesis. This has functional consequences for organotropism of metastasis, as T reg depletion reduces metastasis to tumor-draining lymph nodes, but not to lungs. Mechanistically, we find that T regs control natural killer (NK) cell activation in lymph nodes, thereby facilitating lymph node metastasis. In line, an increased T reg /NK cell ratio is observed in sentinel lymph nodes of breast cancer patients compared with healthy controls. This study highlights that immune regulation of metastatic disease is highly organ dependent. [Display omitted] • Mammary tumorigenesis drives systemic expansion of highly immunosuppressive T regs • Tumor-educated T regs promote lymph node (LN) metastasis but not lung metastasis • T regs promote LN metastasis by local suppression of NK cells in the LN niche • LNs of breast cancer patients have elevated T reg and reduced NK cell accumulation Kos et al. demonstrate that breast cancer development is accompanied by systemic expansion of immunosuppressive regulatory T cells. The phenotype and function of tumor-educated T regs are uniquely shaped by the local tissue environment. Consequently, tumor-educated T regs impair local NK cell activity to enhance metastasis to lymph nodes, but not lungs. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. The role of transforming growth factor β in upper gastrointestinal cancers: A systematic review.
- Author
-
Veen, Linde M., Skrabanja, Tim L.P., Derks, Sarah, de Gruijl, Tanja D., Bijlsma, Maarten F., and van Laarhoven, Hanneke W.M.
- Abstract
Esophageal and gastric malignancies are associated with poor prognosis, in part due to development of recurrences or metastases after curative treatment. The transforming growth factor β (TGF-β) pathway might play a role in the development of treatment resistance. In this systematic review, we provide an overview of preclinical studies investigating the role of TGF-β in esophageal and gastric malignancies. We systematically searched MEDLINE/PubMed and EMBASE for eligible preclinical studies describing the effect of TGF-β or TGF-β inhibition on hallmarks of cancer, such as proliferation, migration, invasion, angiogenesis and immune evasion. In total, 2107 records were screened and 45 articles were included, using mouse models and 45 different cell lines. TGF-β failed to induce apoptosis in twelve of sixteen tested cell lines. TGF-β could either decrease (five cell lines) or increase proliferation (seven cell lines) in gastric cancer cells, but had no effect in esophageal cancer cells. In all esophageal and all but two gastric cancer cell lines, TGF-β increased migratory, adhesive and invasive capacities. In vivo studies showed increased metastasis in response to TGF-β treatment. Additionally, TGF-β was shown to induce vascular endothelial growth factor production and differentiation of cancer-associated fibroblasts and regulatory T-cells. In conclusion, we found that TGF-β enhances hallmarks of cancer in most gastric and esophageal cancer cell lines, but not in all. Therefore, targeting the TGF-β pathway could be an attractive strategy in patients with gastric or esophageal cancer, but additional clinical trials are needed to define patient groups who would benefit most. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Chemically engineered glycan-modified cancer vaccines to mobilize skin dendritic cells.
- Author
-
Duinkerken, Sanne, Li, R. Eveline, van Haften, Floortje J., de Gruijl, Tanja D., Chiodo, Fabrizio, Schetters, Sjoerd T.T., and van Kooyk, Yvette
- Subjects
- *
CANCER vaccines , *DENDRITIC cells , *T cells , *SKIN , *VACCINES - Abstract
Dendritic cell (DC)–targeting vaccines show great promise in increasing antitumor immunity. Glycan-engineered vaccines facilitate both DC targeting and increased uptake by DCs for processing and presentation to CD4+ and CD8+ T cells to induce tumor-specific T-cell responses. However, the complexity of various DC subsets in skin tissues, expressing different glycan-binding receptors that can mediate vaccine uptake or drainage of vaccines via lymphatics directly to the lymph node–resident DCs, complicates the success of vaccines. Moreover, the influx of inflammatory immune cells to the site of vaccination, such as monocytes that differentiate to DCs and coexpress glycan-binding receptors, may contribute to the strength of DC-targeting glycovaccines for future clinical use. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
12. A safety and immunogenicity study of immunization with hVEGF26-104/RFASE in cynomolgus monkeys.
- Author
-
Wentink, Madelon Q., Verheul, Henk M.W., Griffioen, Arjan W., Schafer, Kenneth A., McPherson, Susan, Early, Richard J., van der Vliet, Hans J., and de Gruijl, Tanja D.
- Subjects
- *
VASCULAR endothelial growth factors , *NEOVASCULARIZATION inhibitors , *CANCER , *ANTIGENS , *IMMUNOGENETICS , *KRA - Abstract
Introduction Vascular endothelial growth factor (VEGF) is pivotal in tumor angiogenesis and therapies targeting the VEGF axis are widely used in the clinic for the treatment of cancer. We have developed a therapeutic vaccine targeting human (h)VEGF 165 . hVEGF 26-104 /RFASE is based on the truncated protein hVEGF 26-104 as antigen formulated in an oil-in-water emulsion containing the sulpholipopolysaccharide RFASE as adjuvant. Here we describe the toxicity and immunogenicity of this therapeutic vaccine in cynomolgus monkeys. Methods In total 54 cynomolgus monkeys were used and divided in 7 groups. Groups 1–3 were control groups, either receiving PBS alone (group 1), RFASE alone (group 2) or hVEGF 26-104 alone (group 3). Animals allocated to groups 4–7 received hVEGF 26-104 together with RFASE, but with varying doses of the antigen or the adjuvant. All animals were immunized four times with 2-week intervals and safety and immunogenicity were monitored until 3 days after the final immunization. Results Immunization induced an RFASE adjuvant dependent acute phase response. High titers of antibodies against hVEGF 26-104 and cross-reactive with hVEGF 165 , were found in monkey sera, 28 days after primer immunization. These antibodies were able to inhibit the binding of the monoclonal antibody bevacizumab with hVEGF 165 in a competition ELISA. Moreover, the biological activity of hVEGF 165 could be inhibited by the addition of immunized monkey serum in a VEGF specific bioassay. Importantly, no adverse events commonly observed with VEGF neutralization were observed throughout the study. Conclusion These data show that hVEGF 26-104 /RFASE can be safely administered in cynomolgus monkeys, induces the desired immune response and therefore support the clinical development of this vaccine. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
13. The effects of systemic treatment with aminobisphosphonates and statins on circulating Vγ9Vδ2-T cells in patients with advanced cancer.
- Author
-
Schneiders, Famke L., Huijts, Charlotte M., Reijm, Martine, Bontkes, Hetty J., Verheul, Henk M.W., de Gruijl, Tanja D., and van der Vliet, Hans J.
- Subjects
- *
T cells , *CANCER patients , *ACUTE phase reaction , *TUMOR necrosis factors , *CYTOKINES - Abstract
Aminobisphosphonates (NBP) are used for treatment of metastatic bone disease. Frequently, patients undergoing NBP-treatment experience side-effects, known as acute phase response (APR), resulting from cytokine production by Vγ9Vδ2-T cells. As opposed to NBP, statins reduce intracellular phosphoantigen levels and prevent NBP-induced Vγ9Vδ2-T cell activation in vitro . We conducted a pilot study in patients with (bone-)metastasized malignancies receiving NBP-treatment and evaluated the phenotype and function of circulating Vγ9Vδ2-T cells in vivo and the effects of statins on Vγ9Vδ2-T cell responses and the associated APR. We observed reduced expression of perforin, granzyme B and HLA-DR on Vγ9Vδ2-T cells in patients treated with NBP and statins. However, statins could not prevent NBP-induced changes in circulating Vγ9Vδ2-T cell numbers or production of IFNγ and TNFα. Consistent with this, simvastatin could not prevent the occurrence of APR upon NBP-infusion. These observations call for the exploration of alternative strategies to prevent collateral APR upon NBP treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
14. Immune-competent human skin disease models.
- Author
-
Bergers, Lambert I.J.C., Reijnders, Christianne M.A., van den Broek, Lenie J., Spiekstra, Sander W., de Gruijl, Tanja D., Weijers, Ester M., and Gibbs, Susan
- Subjects
- *
DRUG development , *DRUG use testing , *PLURIPOTENT stem cells , *AUTOIMMUNE diseases , *SKIN diseases , *PSORIASIS - Abstract
All skin diseases have an underlying immune component. Owing to differences in animal and human immunology, the majority of drugs fail in the preclinical or clinical testing phases. Therefore animal alternative methods that incorporate human immunology into in vitro skin disease models are required to move the field forward. This review summarizes the progress, using examples from fibrosis, autoimmune diseases, psoriasis, cancer and contact allergy. The emphasis is on co-cultures and 3D organotypic models. Our conclusion is that current models are inadequate and future developments with immune-competent skin-on-chip models based on induced pluripotent stem cells could provide a next generation of skin models for drug discovery and testing. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
15. In situ Delivery of Antigen to DC-SIGN+CD14+ Dermal Dendritic Cells Results in Enhanced CD8+ T-Cell Responses.
- Author
-
Fehres, Cynthia M, van Beelen, Astrid J, Bruijns, Sven C M, Ambrosini, Martino, Kalay, Hakan, Bloois, Louis van, Unger, Wendy W J, Garcia-Vallejo, Juan J, Storm, Gert, de Gruijl, Tanja D, and Kooyk, Yvette van
- Subjects
- *
DENDRITIC cells , *MACROPHAGES , *T cells , *INTRADERMAL injections , *LIPOSOMES - Abstract
CD14+ dendritic cells (DCs) present in the dermis of human skin represent a large subset of dermal DCs (dDCs) that are considered macrophage-like cells with poor antigen (cross)-presenting capacity and limited migratory potential to the lymph nodes. CD14+ dDC highly express DC-specific ICAM-3-grabbing non-integrin (DC-SIGN), a receptor containing potent endocytic capacity, facilitating intracellular routing of antigens to major histocompatibility complex I and II (MHC-I andII) loading compartments for the presentation to antigen-specific CD8+ and CD4+ T cells. Here we show using a human skin explant model that the in situ targeting of antigens to DC-SIGN using glycan-modified liposomes enhances the antigen-presenting capacity of CD14+ dDCs. Intradermal vaccination of liposomes modified with the DC-SIGN-targeting glycan LewisX, containing melanoma antigens (MART-1 or Gp100), accumulated in CD14+ dDCs and resulted in enhanced Gp100- or MART-1-specific CD8+ T-cell responses. Simultaneous intradermal injection of the cytokines GM-CSF and IL-4 as adjuvant enhanced the migration of the skin DCs and increased the expression of DC-SIGN on the CD14+ and CD1a+ dDCs. These data demonstrate that human CD14+ dDCs exhibit potent cross-presenting capacity when targeted in situ through DC-SIGN. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
16. Bispecific antibody platforms for cancer immunotherapy.
- Author
-
Lameris, Roeland, de Bruin, Renée C.G., Schneiders, Famke L., van Bergen en Henegouwen, Paul M.P., Verheul, Henk M.W., de Gruijl, Tanja D., and van der Vliet, Hans J.
- Subjects
- *
CANCER treatment , *IMMUNOTHERAPY , *BIOENGINEERING , *TUMOR immunology , *ANTINEOPLASTIC agents , *BISPECIFIC antibodies - Abstract
Over the past decades advances in bioengineering and expanded insight in tumor immunology have resulted in the emergence of novel bispecific antibody (bsAb) constructs that are capable of redirecting immune effector cells to the tumor microenvironment. (Pre-) clinical studies of various bsAb constructs have shown impressive results in terms of immune effector cell retargeting, target dependent activation and the induction of anti-tumor responses. This review summarizes recent advances in the field of bsAb-therapy and limitations that were encountered. Furthermore, we will discuss potential future developments that can be expected to take the bsAb approach successfully forward. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
17. CCL5 and CCL20 mediate immigration of Langerhans cells into the epidermis of full thickness human skin equivalents
- Author
-
Ouwehand, Krista, Spiekstra, Sander W., Waaijman, Taco, Breetveld, Melanie, Scheper, Rik J., de Gruijl, Tanja D., and Gibbs, Susan
- Subjects
- *
LANGERHANS cells , *CELL migration , *EPIDERMIS , *KERATINOCYTES , *TUMOR necrosis factors , *TRANSFORMING growth factors , *CHEMOKINES - Abstract
Abstract: Epidermal Langerhans cells (LC) play a key role in initiation and regulation of immune responses. Whereas LC migration out of the epidermis upon environmental assault is extensively studied, the mechanisms involved in the (re)population of the epidermis with LC are poorly understood. Here, we investigated the immigration of LC derived from the human MUTZ-3 cell line (MUTZ-LC) into the epidermis of a full thickness skin equivalent, comprising a fully differentiated epidermis on a fibroblast-populated dermis. MUTZ-LC were used to determine which epidermis-derived chemokines play a role in mediating LC trans-dermal migration into the epidermis. We found evidence for a role of keratinocyte-derived CCL5 and CCL20 in the chemo-attraction of MUTZ-LC. Neutralizing antibodies against CCL5 and CCL20 blocked LC migration towards keratinocytes. Secretion of these two chemokines was associated with incorporation of MUTZ-LC into the epidermis of full thickness skin equivalents. In conclusion, our findings suggest that epidermis derived CCL5 and CCL20 are pivotal mediators in recruitment of LC into the epidermis. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
18. Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells
- Author
-
Unger, Wendy W.J., van Beelen, Astrid J., Bruijns, Sven C., Joshi, Medha, Fehres, Cynthia M., van Bloois, Louis, Verstege, Marleen I., Ambrosini, Martino, Kalay, Hakan, Nazmi, Kamran, Bolscher, Jan G., Hooijberg, Erik, de Gruijl, Tanja D., Storm, Gert, and van Kooyk, Yvette
- Subjects
- *
CANCER treatment , *IMMUNOTHERAPY , *T cell differentiation , *DENDRITIC cells , *TARGETED drug delivery , *LIPOSOMES , *GENE expression - Abstract
Abstract: Cancer immunotherapy requires potent tumor-specific CD8+ and CD4+ T-cell responses, initiated by dendritic cells (DCs). Tumor antigens can be specifically targeted to DCs in vivo by exploiting their expression of C-type lectin receptors (CLR), which bind carbohydrate structures on antigens, resulting in internalization and antigen presentation to T-cells. We explored the potential of glycan-modified liposomes to target antigens to DCs to boost murine and human T-cell responses. Since DC-SIGN is a CLR expressed on DCs, liposomes were modified with DC-SIGN-binding glycans Lewis (Le)B or LeX. Glycan modification of liposomes resulted in increased binding and internalization by BMDCs expressing human DC-SIGN. In the presence of LPS, this led to 100-fold more efficient presentation of the encapsulated antigens to CD4+ and CD8+ T-cells compared to unmodified liposomes or soluble antigen. Similarly, incubation of human moDC with melanoma antigen MART-1-encapsulated liposomes coated with LeX in the presence of LPS led to enhanced antigen-presentation to MART-1-specific CD8+ T-cell clones. Moreover, this formulation drove primary CD8+ T-cells to differentiate into high numbers of tetramer-specific, IFN-γ-producing effector T-cells. Together, our data demonstrate the potency of a glycoliposome-based vaccine targeting DC-SIGN for CD4+ and CD8+ effector T-cell activation. This approach may offer improved options for treatment of cancer patients and opens the way to in situ DC-targeted vaccination. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
19. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
- Author
-
van den Eertwegh, Alfons JM, Versluis, Jurjen, van den Berg, H Pieter, Santegoets, Saskia JAM, van Moorselaar, R Jeroen A, van der Sluis, Tim M, Gall, Helen E, Harding, Thomas C, Jooss, Karin, Lowy, Israel, Pinedo, Herbert M, Scheper, Rik J, Stam, Anita GM, von Blomberg, B Mary E, de Gruijl, Tanja D, Hege, Kristen, Sacks, Natalie, and Gerritsen, Winald R
- Subjects
- *
IMMUNOTHERAPY , *GRANULOCYTE-macrophage colony-stimulating factor , *IPILIMUMAB , *PROSTATE cancer treatment , *CYTOTOXIC T lymphocyte-associated molecule-4 , *VACCINATION , *METASTASIS - Abstract
Summary: Background: The granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells vaccine (GVAX) has antitumour activity against prostate cancer; preclinical studies have shown potent synergy when combined with ipilimumab, an antibody that blocks cytotoxic T-lymphocyte antigen 4. We aimed to assess the safety of combined treatment with GVAX and ipilimumab in patients with metastatic castration-resistant prostate cancer (mCRPC). Methods: We did an open-labelled, single-centre, dose-escalation study of ipilimumab concurrent with a fixed dose of GVAX, with a subsequent expansion phase, both at the VU University Medical Centre (Amsterdam, Netherlands). Eligible patients had documented mCRPC and had not been previously treated with chemotherapy. All patients received a 5×108 cell priming dose of GVAX intradermally on day 1 with subsequent intradermal injections of 3×108 cells every 2 weeks for 24 weeks. The vaccinations were combined with intravenous ipilimumab every 4 weeks. We enrolled patients in cohorts of three; each cohort received an escalating dose of ipilimumab at 0·3, 1·0, 3·0, or 5·0 mg/kg. Our primary endpoint was safety. This study is registered with ClinicalTrials.gov, number NCT01510288. Findings: We enrolled 12 patients into our dose-escalation cohort. We did not record any severe immune-related adverse events at the first two dose levels. At the 3·0 mg/kg dose level, one patient had grade 2 and two patients grade 3 hypophysitis; at the 5·0 mg/kg dose level, two patients had grade 3 hypophysitis and one patient developed grade 4 sarcoid alveolitis (a dose-limiting toxic effect). Due to observed clinical activity and toxic events, we decided to expand the 3·0 mg/kg dose level, rather than enrol a further three patients at the 5·0 mg/kg level. 16 patients were enrolled in the expansion cohort, two of whom developed grade 2 hypophysitis, three colitis (one grade 1 and two grade 2), and one grade 3 hepatitis—all immune-related adverse events. The most common adverse events noted in all 28 patients were injection-site reactions (grade 1–2 events seen in all patients), fatigue (grade 1–2 in 20 patients, grade 3 in two), and pyrexia (grade 1–2 in 15 patients, grade 3 in one). 50% or greater declines in prostate-specific antigen from baseline was recorded in seven patients (25%); all had received 3·0 mg/kg or 5·0 mg/kg ipilimumab. Interpretation: GVAX combined with 3·0 mg/kg ipilimumab is tolerable and safe for patients with mCRPC. Further research on the combined treatment of patients with mCRPC with vaccination and ipilimumab is warranted. Funding: Cell Genesys Inc, Prostate Cancer Foundation, Dutch Cancer Society (KWF-VU 2006-3697), and Foundation Stichting VUmc Cancer Center Amsterdam. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
20. Feasibility of flowcytometric quantitation of immune effector cell subsets in the sentinel lymph node of the breast after cryopreservation
- Author
-
van Pul, Kim M., Vuylsteke, Ronald J.C.L.M., Bril, Herman, Stockmann, Hein B.A.C., and de Gruijl, Tanja D.
- Subjects
- *
FLOW cytometry , *SENTINEL lymph nodes , *BREAST cancer , *CRYOPRESERVATION of cells , *DENDRITIC cells , *T cells - Abstract
Abstract: The sentinel lymph node (SLN) is an emerging focus for immunological research in breast cancer. Cryopreservation of SLN single-cell suspensions allows for simultaneous phenotypic multi-parameter analyses and minimizes operator dependent variability. This is of particular importance for immunomonitoring of large multicenter trials. However, little data are available regarding the influence of cryopreservation on phenotypic characteristics of lymph node dendritic cells and T cells. In this study we assessed the feasibility of cryopreservation of viable SLN cell samples for flowcytometric analysis, by comparing quantitative analyses of SLN cell samples after freeze-thawing with direct analysis of fresh SLN cell samples. SLN were collected from nine breast cancer patients. From each SLN cell sample, half was used for immediate analysis and half was analyzed after cryopreservation and thawing. Conventional dendritic cell (cDC) and T cell subsets were quantified and phenotypically characterized by flow cytometry. The observed frequencies of both CD1a+ and CD1a−CD11c+CD14− cDC subsets showed significant correlation between the fresh and frozen-thawed samples. Similar high correlations were found for CD83 and CD86 expression markers on the more frequent (>0.2%) CD1a+ and CD1a−CD11c+CD14− cDC subset, but not on the low-frequency (<0.2%) CD1a+CD11c+CD14+ cDC subset. CD4/CD8 T cell ratios were comparable and were significantly correlated pre- and post-freezing. Regulatory CD4+CD25hi T cell frequencies and their FoxP3 expression levels were significantly higher after freezing–thawing than in the freshly analyzed samples. Nevertheless, a highly significant correlation was found for both parameters pre- and post-freezing. Cryopreservation and thawing seems a valid and practical alternative to direct analysis of fresh viable lymph node cells, without introducing cryo-dependent variance between SLN samples. However, enumeration of low-frequency cell populations and assessment of their marker expression levels are less reliable after cryopreservation and should be assessed and considered in the design of each clinical trial. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
21. Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine
- Author
-
Hangalapura, Basav N., Oosterhoff, Dinja, Gupta, Tarun, de Groot, Jan, Wijnands, Pepijn G.J.T.B., van Beusechem, Victor W., den Haan, Joke, Tüting, Thomas, van den Eertwegh, Alfons J.M., Curiel, David T., Scheper, Rik J., and de Gruijl, Tanja D.
- Subjects
- *
ANTINEOPLASTIC agents , *ADENOVIRUSES , *MELANOMA , *VIRAL vaccines , *IMMUNOTHERAPY , *COMPARATIVE studies , *LYMPH nodes , *ANTIGENS , *DRUG administration , *VACCINATION - Abstract
Abstract: Adenovirus (Ad)-based vaccines are considered for cancer immunotherapy, yet, detailed knowledge on their mechanism of action and optimal delivery route for anti-tumor efficacy is lacking. Here, we compared the anti-tumor efficacy of an Ad-based melanoma vaccine after intradermal, intravenous, intranasal or intraperitoneal delivery in the B16F10 melanoma model. The intradermal route induced superior systemic anti-melanoma immunity which was MyD88 signaling-dependent. Predominant transduction of non-professional antigen-presenting cells at the dermal vaccination sites and draining lymph nodes, suggested a role for cross-presentation, which was confirmed in vitro. We conclude that the dermis provides an optimal route of entry for Ad-based vaccines for high-efficacy systemic anti-tumor immunization and that this immunization likely involves cross-priming events in the draining lymph nodes. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
22. Irritant-Induced Migration of Langerhans Cells Coincides with an IL-10-Dependent Switch to a Macrophage-Like Phenotype.
- Author
-
Ouwehand, Krista, Oosterhoff, Dinja, Breetveld, Melanie, Scheper, Rik J., de Gruijl, Tanja D., and Gibbs, Susan
- Subjects
- *
LANGERHANS cells , *MACROPHAGES , *PHENOTYPES , *LYMPH node diseases , *SKIN inflammation , *IMMUNOGLOBULINS , *DISEASES - Abstract
Langerhans cells (LCs) migrate after topical exposure of the skin to irritants, despite the supposed independence of irritant contact dermatitis from adaptive immunity. Whereas allergen-activated LCs are known to migrate to the draining lymph nodes (LNs), the fate of migrated LCs upon topical irritant exposure is unknown. Here, we identified a phenotypic switch of LCs after their migration into the dermis upon irritant exposure. With the aid of ex vivo intact human skin and epidermal sheets, we show that dermal fibroblasts are necessary for an IL-10-dependent postmigrational phenotypic switch of LCs into macrophage-like cells. Exposure of ex vivo skin to a panel of seven irritants resulted in a decrease in the number of CD1a+ cells and an increase in CD14+/CD68+ cells in the dermis. Neutralizing antibodies against IL-10 totally inhibited the phenotypic LC-to-macrophage transition, but did not influence the migration of CD1a+ cells. Exposure of epidermal sheets to irritants resulted in a fibroblast-dependent LC-to-CD14+/CD68+ switch coinciding with migration, which could be totally inhibited by neutralizing antibodies against either IL-10 or CCL2/CCL5 (two chemokines responsible for epidermal-to-dermal migration). We have thus identified an IL-10-dependent phenotypic switch of LCs into macrophage-like cells upon irritant exposure and emigration from the epidermis. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
23. Comparison of a novel CXCL12/CCL5 dependent migration assay with CXCL8 secretion and CD86 expression for distinguishing sensitizers from non-sensitizers using MUTZ-3 Langerhans cells
- Author
-
Ouwehand, Krista, Spiekstra, Sander W., Reinders, Judith, Scheper, Rik J., de Gruijl, Tanja D., and Gibbs, Susan
- Subjects
- *
CELL migration , *SECRETION , *GENE expression , *LANGERHANS cells , *MYELOID leukemia , *CELL lines , *IRRITANTS (Drugs) , *DENDRITIC cells , *SALICYLIC acid , *TUMOR necrosis factors - Abstract
Abstract: As the induction of contact hypersensitivity is the result of a series of cellular processes, including maturation and migration of epidermal dendritic cells (Langerhans cells (LC)), a battery of assays based on these in vivo events might provide a robust in vitro predictability model for distinguishing sensitizers from non-sensitizers. Therefore, assays with read-out for changes in CD86 expression and CXCL8 secretion were compared with a novel functional assay based on the in vitro migratory behaviour of LC. In all three assays LC derived from the human myeloid-leukaemia-cell-line MUTZ-3 (MUTZ-LC) were used. Exposure of MUTZ-LC to a panel of five sensitizers and three non-sensitizers resulted in increased CD86 expression in only 3/5 sensitizers, but also in 1/3 non-sensitizers. In contrast, CXCL8 secretion was uniformly increased after exposure to all sensitizers, but not after exposure to non-sensitizers. In a transwell migration assay, preferential migration of sensitizer-exposed MUTZ-LC towards CXCL12 was observed (5/5 sensitizers), whereas non-sensitizer-exposed MUTZ-LC only migrated towards CCL5 (3/3 non-sensitizers). In conclusion, the novel MUTZ-LC migration assay and analysis of CXCL8 secretion proved to be more successful than analysis of CD86 in predicting sensitizers from non-sensitizers and therefore warrant further investigation in the field of in vitro assay development. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
24. A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo
- Author
-
Thacker, Erin E., Nakayama, Masaharu, Smith, Bruce F., Bird, R. Curtis, Muminova, Zhanat, Strong, Theresa V., Timares, Laura, Korokhov, Nikolay, O’Neill, Ann Marie, de Gruijl, Tanja D., Glasgow, Joel N., Tani, Kenzaburo, and Curiel, David T.
- Subjects
- *
ADENOVIRUSES , *GENETIC vectors , *MICROBIAL genetic engineering , *IMMUNOREGULATION , *DENDRITIC cells , *TUMOR antigens , *CANCER vaccines , *CANCER immunotherapy , *LIGANDS (Biochemistry) , *LABORATORY dogs - Abstract
Abstract: Targeting viral vectors encoding tumor-associated antigens to dendritic cells (DCs) in vivo is likely to enhance the effectiveness of immunotherapeutic cancer vaccines. We have previously shown that genetic modification of adenovirus (Ad) 5 to incorporate CD40 ligand (CD40L) rather than native fiber allows selective transduction and activation of DCs in vitro. Here, we examine the capacity of this targeted vector to induce immune responses to the tumor antigen CEA in a stringent in vivo canine model. CD40-targeted Ad5 transduced canine DCs via the CD40-CD40L pathway in vitro, and following vaccination of healthy dogs, CD40-targeted Ad5 induced strong anti-CEA cellular and humoral responses. These data validate the canine model for future translational studies and suggest targeting of Ad5 vectors to CD40 for in vivo delivery of tumor antigens to DCs is a feasible approach for successful cancer therapy. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
25. The ABC of dendritic cell development and function
- Author
-
van de Ven, Rieneke, Scheffer, George L., Scheper, Rik J., and de Gruijl, Tanja D.
- Subjects
- *
ATP-binding cassette transporters , *DENDRITIC cells , *MULTIDRUG resistance , *IMMUNE response , *IMMUNOLOGICAL adjuvants , *GENE expression , *IMMUNOTHERAPY - Abstract
ATP-binding cassette (ABC) transporters are known for their involvement in clinical multidrug resistance (MDR) and their physiological defensive functions in barrier organs. More recently, attention has been focused on their possible involvement in the regulation of immune responses following the identification of their substrates as known immunomodulating agents (e.g. prostaglandins, leukotrienes and cyclic nucleotides) and their functional expression in various immune effector cells, most notably in dendritic cells (DCs). This review addresses the possible roles of ABC transporters in DC development and function, as well as the putative immunostimulatory potential of their cytostatic substrates and how this knowledge might benefit DC-based chemo-immunotherapies. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
26. Unimpaired immune functions in the absence of Mrp4 (Abcc4)
- Author
-
van de Ven, Rieneke, de Groot, Jan, Reurs, Anneke W., Wijnands, Pepijn G.J.T.B., van de Wetering, Koen, Schuetz, John D., de Gruijl, Tanja D., Scheper, Rik J., and Scheffer, George L.
- Subjects
- *
IMMUNE response , *IMMUNOLOGY , *IMMUNOTHERAPY , *DENDRITIC cells - Abstract
Abstract: Dendritic cell (DC) migration to draining lymph nodes is important for the initiation of an effective immune response. Recently we reported that the human ATP-binding cassette (ABC) transporter multidrug resistance protein 4 (MRP4 and ABCC4) is required for the migration of human DC. Since the ABC transporter MRP1 (ABCC1) was previously shown to play a role in both human and mouse DC migration, we here studied whether Mrp4 is similarly required for DC migration in mice and whether the absence of Mrp4 interferes with the generation of an immune response. Immunological responses were compared in wild-type FVB (FVBwt), FVB Mrp4 knockout (KO) or FVB Mrp4/5 double knockout (dKO) mice. Skin, a preferred immunization site, was analyzed for DC markers, as well as for Mrp1 and Mrp4 expression. Whereas Mrp1 was abundantly present within FVBwt skin, only few Mrp4 expressing cells were detected. In addition, no Mrp4 protein expression was detected on in vitro cultured FVBwt bone marrow-derived DC (BM-DC). DC migration from murine ear skin was unaltered between FVBwt and MRP4/5 dKO animals. The absence of Mrp4 also had no effect on immune responses upon allergen sensitization, immunization or oral tolerance induction. We thus conclude that in contrast to its human counterpart, murine Mrp4 is not involved in DC migration, nor indeed, in the generation of an effective immune response. These data reveal disparities in the physiological role of ABC transporters between species, which may derive from differences in substrate specificity. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
27. Immunomodulation of the melanoma sentinel lymph node: A novel adjuvant therapeutic option
- Author
-
Molenkamp, Barbara G., van Leeuwen, Paul A.M., van den Eertwegh, Alfons J.M., Sluijter, Berbel J.R., Scheper, Rik J., Meijer, Sybren, and de Gruijl, Tanja D.
- Subjects
- *
TUMORS , *CANCER treatment , *CANCER patients , *IMMUNOLOGICAL adjuvants - Abstract
Abstract: Cutaneous melanoma is the most aggressive type of skin cancer. Paradoxically, melanoma is also the most immunogenic tumour identified to date: tumour-reactive T cells are detectable both in the blood and in tumour-draining lymph nodes (TDLN) of melanoma patients and their frequency can be increased by specific vaccination. However, early melanoma development is accompanied by impaired immune effector functions in the initial TDLN, the sentinel lymph node (SLN). Most notably, a reduced frequency and activation state of dendritic cells (DC) interferes with the uptake and presentation of tumour-associated antigens (TAA) to specific anti-tumour cytotoxic T-lymphocytes (CTL) and T helper cells (Th). These impaired immune effector functions may contribute to the early metastatic events that are associated with this tumour type. Since complete surgical excision at an early stage remains the only curative treatment option (adjuvant therapy options are limited and show no survival benefits), immunopotentiation of the SLN to jump-start or boost tumour specific immunity in early stage melanoma may be a valuable adjuvant treatment option that can be generally applied with minimal discomfort to the patient. Early clinical studies indicate that local Granulocyte/Macrophage-Colony Stimulating Factor (GM-CSF) or Cytosine-phosphate-Guanine (CpG) administration leads to activation of different DC subsets and conditions the SLN microenvironment to be more conducive to the generation of T-cell-mediated anti-tumour immunity. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
28. CD40-targeted adenoviral gene transfer to dendritic cells through the use of a novel bispecific single-chain Fv antibody enhances cytotoxic T cell activation
- Author
-
Brandão, Joana G., Scheper, Rik J., Lougheed, Sinéad M., Curiel, David T., Tillman, Bryan W., Gerritsen, Winald R., van den Eertwegh, Alfons J.M., Pinedo, Herbert M., Haisma, Hidde J., and de Gruijl, Tanja D.
- Subjects
- *
ADENOVIRUS diseases , *DENDRITIC cells - Abstract
Adenoviral (Ad) transduction of dendritic cells (DC) is a promising vaccination strategy. However, clinical applicability of Ad vectors is hampered by the necessity to use high titers of infectious Ad particles for efficient DC transduction. Here, we report on the production of a bacterially expressed bispecific conjugate, consisting of a fusion of recombinant single-chain (sc) mAb Fv fragments, which bind and neutralize the Ad fiber knob (through the S11 mAb scFv) and retarget Ad to CD40 on the DC surface (through the G28-5 mAb scFv). We show that this bispecific scFv fusion protein significantly enhances transduction efficiency of monocyte-derived DC (MoDC), reduces the amount of virus needed for a given level of transduction, and increases the ability of MoDC to activate CTL in an antigen specific manner. This single-component conjugate may prove to be a valuable immunotherapeutic tool for the targeting of Ad to DC in vivo. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.